{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-298005","form_type":"8-K","ticker":"MCRB","cik":"0001609809","company_name":"Seres Therapeutics, Inc.","filed_at":"2026-07-08T12:00:09+00:00","discovered_at":"2026-07-08T12:05:00.259038+00:00","generated_at":"2026-07-08T12:05:19.784368+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Seres reports 80% immunosuppressive-free clinical response for SER-155 in irEC trial","bullets":["12 of 15 patients (80%) achieved primary endpoint: ≥1-grade diarrhea improvement without immunosuppressives at Day 15.","5 of 15 (33%) achieved complete remission (Grade 0 diarrhea) at Day 15; 2 of 15 (13%) maintained at Day 43.","SER-155 well tolerated; no drug-related serious adverse events or bloodstream infections through Day 43.","Biomarkers (fecal calprotectin, albumin) showed statistically significant reductions at Day 43, indicating reduced GI inflammation.","Company engaging with potential partners for SER-155 development in irEC and seeking funding for allo-HCT Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-298005","json":"https://secwatch.observer/filing/0001193125-26-298005.json","markdown":"https://secwatch.observer/filing/0001193125-26-298005.md","text":"https://secwatch.observer/filing/0001193125-26-298005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/0001193125-26-298005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/d130829d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-08T12:05:19.784368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}